BMRA vs ZCMD

The Advanced Deterministic Scorecard reveals severe financial distress with a Piotroski F-Score of just 1/9, indicating extremely weak fundamental health. Despite a seemingly healthy Current Ratio of 3.25 and low Debt/Equity of 0.06, the company is plagued by deep profitability issues, including a -90.31% profit margin and -84.30% ROE. Revenue has declined by 26% year-over-year, and the stock has lost 95.7% of its value over five years, reflecting persistent operational failures and lack of investor confidence. The absence of an Altman Z-Score due to incomplete data further limits confidence in solvency assessments, but the overwhelming negative trends in earnings, margins, and price performance dominate the outlook.

ZCMD presents a classic 'value trap' profile, characterized by a stable Piotroski F-Score of 6/9 and an exceptionally strong balance sheet (zero debt, 11.11 current ratio) contrasted against catastrophic operational decay. While the stock trades at a deep discount to book value (P/B 0.32), the company is suffering from severe revenue contraction (-23.2% YoY) and an unsustainable operating margin of -92%. The long-term price performance is devastating, with a 98.6% decline over five years, suggesting the market has fundamentally lost confidence in the business model despite the liquidity cushion.